OVARIAN CANCER

OVARIAN CANCER

Displaying 10 out of 14 results

  1. FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the

    AstraZeneca-Merck Lynparza wins approval in China for ovarian cancer treatment

    AstraZeneca Plc and Merck & Co Inc said on Thursday that their drug, Lynparza, won approval in China as a first line treatment for a from of ...
  2. FILE PHOTO: The GSK logo is seen on top of GSK Asia House in Singapore

    US FDA okays wider use of GSK ovarian cancer drug

    GlaxoSmithKline said on Wednesday U.S. regulators approved its ovarian cancer treatment Zejula for wider use in some advanced cancers, in a boost ...
  3. FILE PHOTO: A Johnson & Johnson building is shown in Irvine, California

    Missouri appeals court overturns US$110 million Johnson & Johnson talc verdict

    A Missouri appeals court overturned a US$110 million verdict against Johnson & Johnson in a lawsuit by a Virginia woman who says she developed ...
  4. FILE PHOTO: The GSK logo is seen on top of GSK Asia House in Singapore

    GlaxoSmithKline's cancer therapy cuts risk of disease progression or death by 38per cent

    GlaxoSmithKline plc said on Monday its maintenance therapy for a form of ovarian cancer reduced the risk of disease progression or death by 38per ...
  5. FILE PHOTO: The GSK logo is seen on top of GSK Asia House in Singapore

    Separate GSK, AstraZeneca trial results may widen ovarian cancer drug use

    GlaxoSmithKline and AstraZeneca both reported trial results that will likely make their competing drugs available to a wider group of ovarian ...
  6. FILE PHOTO: Logo of AstraZeneca is displayed on a screen on the floor at the New York Stock Exchang

    AstraZeneca scores win in race to treat ovarian cancer

    AstraZeneca has made further headway in the race with larger competitor GlaxoSmithKline's to use a promising new class of drugs to treat ovarian ...
  7. The GSK logo is seen on top of GSK Asia House in Singapore

    GSK's ovarian cancer treatment meets main goal in late-stage study

    GlaxoSmithKline said on Monday a late-stage study testing Zejula as a maintenance therapy in patients with first-line ovarian cancer showed ...